AUS
NZ
UK
CA
USA
IND
Highlights
- Revenue Growth: 5% increase in HY25, reaching $8.48 billion at constant currency (CC).
- Profit Expansion: Underlying net profit rose 5% at CC to $2.11 billion.
- Dividend Boost: Interim dividend jumped 16% to A$2.08 per share.
CSL (ASX:CSL), a global biotechnology leader, recently announced its half-year results for FY25, drawing investor attention with solid performance despite market headwinds. The company's diversified portfolio in blood plasma products, vaccines, and pharmaceuticals contributed to steady growth, reinforcing its position in the healthcare industry.
Financial Performance & Growth Drivers
For the six months ending December 31, 2024, CSL reported a 5% revenue increase at CC, bringing total revenue to $8.48 billion. Underlying net profit also climbed 5% to $2.11 billion at CC, while statutory net profit grew 6% to $2.01 billion. The company’s focus on operational efficiency and strategic investments continues to yield positive results, as reflected in its 16% dividend increase to A$2.08 per share.
Strong Performance in Core Segments
CSL Behring, the company’s largest division, experienced 10% sales growth, driven by a 15% surge in immunoglobulin (Ig) sales to $3.1 billion. Other key products such as albumin and haemophilia treatments also saw growth, rising 9% and 11%, respectively.
However, the Seqirus vaccine business faced a 9% decline in revenue to $1.66 billion, primarily due to lower influenza immunization rates in the U.S. Meanwhile, CSL’s Vifor unit grew 6% to $1.08 billion, benefiting from strong iron demand in Europe and expanding nephrology treatments.
Operational & R&D Developments
CSL is actively working on improving gross profit margins, with cost-saving initiatives progressing as planned. Plasma collections continue to rise, and the rollout of RIKA plasmapheresis devices in the U.S. remains on track for completion by June 2025.
On the research front, R&D expenses declined 4% to $646 million, attributed to the conclusion of several projects. The company expects R&D investment to remain around 10% of total revenue for FY25 as it advances innovation across its portfolio.
Future Outlook
CSL remains confident in its ability to deliver double-digit earnings growth over the medium term. For FY25, the company expects revenue growth of 5%-7% at CC, with underlying net profit projected to be between $3.2 billion and $3.3 billion, representing 10%-13% growth.
While some market challenges persist, CSL (ASX:CSL) continues to strengthen its core business, positioning itself for sustained long-term growth.
